IL-17A inhibitor-induced leucocytoclastic vasculitis is responsive to IL-23 blockade in a psoriatic arthritis patient

Introduction Secukinumab is a fully humanised monoclonal antibody directed at interleukin 17A (IL-17A) which has been widely used for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis.1 The use of secukinumab increases the risk of mucocutaneous candidiasis, but little is known about other specific cutaneous adverse events (AEs). Of note, few cases of secukinumab-induced leucocytoclastic vasculitis (LCV) have been described in the literature.2 3 Case presentation A 59-year-old man with a history of plaque psoriasis and PsA refractory to first-line and second-line treatment presented with worsening disease. To manage the PsA of this patient, first-line therapy included non-steroidal anti-inflammatory drugs, such as ibuprofen and methotrexate, as a non-biological disease-modifying antirheumatic drug, while the tumour necrosis factor inhibitor infliximab was used as a second-line therapy. The treatment with infliximab had controlled his disease burden for 8 years until the...
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Letter Source Type: research